Keyphrases
Melanoma
73%
Isolated Limb Perfusion
44%
Tumor Necrosis Factor-α
44%
Melphalan
35%
Tumor
30%
Metastatic Melanoma
25%
Melanoma Patients
23%
Interferon-α (IFN-α)
21%
Adjuvant Therapy
16%
Cancer Treatment
16%
Sentinel Lymph Node
15%
EORTC
15%
Interleukin-2
15%
European Organizations
13%
Overall Survival
13%
Perfusion
13%
Prognostic Factors
12%
In Cancer
12%
Stage III Melanoma
10%
Phase II Trial
10%
Cancer Therapy
10%
Soft Tissue Sarcoma
9%
Cancer Patients
9%
Sentinel Lymph Node Biopsy
9%
Ipilimumab
9%
Chemotherapy
8%
Malignant Melanoma
8%
Primary Melanoma
8%
Tumor Cells
8%
Isolated Perfusion
8%
High Dose
8%
High Risk
7%
Hazard Ratio
7%
Tumor Response
7%
Clinical Trials
7%
Placebo
7%
Response Rate
7%
Pembrolizumab
7%
Natural Killer Cells
6%
In-transit Metastasis
6%
Advanced Melanoma
6%
Doxorubicin
6%
Programmed Death-ligand 1 (PD-L1)
6%
Locally Advanced
6%
Sarcoma
6%
Antitumor Effect
6%
Extremity Soft Tissue Sarcoma
6%
Distant Metastasis
6%
Confidence Interval
5%
T Cells
5%
Medicine and Dentistry
Melanoma
100%
Neoplasm
46%
Limb Perfusion
35%
Tumor Necrosis Factor
30%
Melphalan
28%
Malignant Neoplasm
22%
Sentinel Node
18%
Immunotherapy
15%
Metastatic Carcinoma
14%
Disease
13%
Surgery
13%
Overall Survival
13%
Limb
12%
Adjuvant Therapy
12%
Metastatic Melanoma
12%
Soft Tissue Sarcoma
11%
Cancer Treatment
11%
Recurrent Disease
11%
Cutaneous Melanoma
11%
Prognostic Factor
10%
Interferon
10%
Retroperitoneal Lymph Node Dissection
10%
Cancer Therapy
8%
Biopsy Technique
8%
Chemotherapy
7%
Breast Cancer
7%
Ipilimumab
7%
Recurrence Free Survival
7%
Hazard Ratio
7%
Tumor Necrosis
6%
Connective Tissue Cancer
6%
Pembrolizumab
6%
Placebo
6%
Clinical Trial
6%
In-Transit Metastasis
6%
Oncology
5%
Monoclonal Antibody
5%
Rectum Cancer
5%
Radiation Therapy
5%
Survival Rate
5%
Arm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
64%
Neoplasm
46%
Malignant Neoplasm
36%
Tumor Necrosis Factor
28%
Limb Perfusion
25%
Melphalan
21%
Immunotherapy
13%
Interferon
13%
Overall Survival
11%
Disease
10%
Metastatic Melanoma
9%
Chemotherapy
9%
Soft Tissue Sarcoma
8%
Interleukin 2
8%
Recurrence Free Survival
7%
Doxorubicin
7%
Recurrent Disease
7%
Liposome
6%
Ipilimumab
6%
Placebo
6%
Clinical Trial
6%
Tumor Necrosis
6%
Connective Tissue Cancer
5%
Pembrolizumab
5%
Cytokine
5%
Hyperthermia
5%